AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psychedelic Space?

AbbVie (ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin (GM-2505), in a deal valued at up to $1.2 billion in upfront and milestone payments. The agreement gives AbbVie exclusive rights to advance the asset’s development for moderate-to-severe major depressive disorder (MDD).

As part of the transaction, Gilgamesh will spin off a new company—Gilgamesh Pharma Inc.—to continue developing its other programs, including blixeprodil (GM-1020), a cardio-safe ibogaine analog, and its M1/M4 agonist program. The companies’ existing collaboration and option-to-license agreement will transfer to the new entity. The transaction is subject to customary closing conditions.

Phase 2a Trial Results Demonstrate Bretisilocin’s Antidepressant Potential

AbbVie and Gilgamesh reported that bretisilocin, an experimental next-generation psychedelic-style antidepressant and a novel short-acting serotonin (5-HT_₂A) receptor agonist and serotonin releaser, produced a statistically significant and clinically meaningful reduction in depressive symptoms in a Phase 2a trial. A single 10 mg dose delivered a 21.6-point drop on the MADRS scale by Day 14, compared with a 12.1-point reduction with a 1 mg active comparator (p = 0.003), with no serious adverse events reported.

These findings point to bretisilocin’s potential to stand apart from earlier-generation compounds. The difference indicates not only robust statistical separation but also a large treatment effect considered clinically relevant for patients with major depressive disorder. Importantly, no serious adverse events were observed, suggesting a favorable safety profile at this stage. This early profile supports AbbVie’s decision to prioritize late-stage development.

Unlike many classic psychedelics, bretisilocin showed a shorter psychoactive duration while maintaining sustained therapeutic benefits, a combination that may improve patient tolerability and treatment practicality in real-world settings. This dual advantage could shape future clinical adoption and position the drug competitively within emerging MDD therapies.

Psychedelic-Based Therapies, such as Bretisilocin, Gain Momentum in Mental Health

AbbVie’s acquisition marks its strategic entry into the growing market for psychedelic‑style treatments in psychiatry. Analysts estimate that the psychedelic compounds market could climb to as high as US$50 billion globally, while current valuations of the psychedelic drugs sector range from US$3.9 billion to US$4.1 billion in 2025, with forecasted growth to US$7.8 billion or more by 2030. MDD treatments overall accounted for around US$12 billion in 2025, with projections reaching US$15.8 billion by 2035. This backdrop highlights the opportunity emerging for novel, rapid‑acting antidepressants.

1. Pharmaceutical Giants Embrace Psychedelic Innovation

AbbVie now joins peers like Johnson & Johnson, Compass Pathways, MindMed, and others in investing in next‑generation psychiatric therapies. This strategic pivot underscores increased industry confidence in the potential of such compounds to fill gaps left by conventional treatments. Effectively, the psychedelic‑style antidepressant space features a range of investigational therapies advancing rapidly:

• 5‑MeO‑DMT (GH001) from GH Research achieved remission in 87.5% of patients at Day 7 in a Phase 2 trial for treatment‑resistant depression, with a 15.5‑point MADRS reduction versus placebo; the compound proceeds toward Phase 2b testing.
• Luvesilocin (RE104), a pro‑drug of a synthetic psychedelic, entered Phase II trials for postpartum depression and TRD, offering a new chemical approach to rapid‑acting intervention.
• MDMA‑assisted psychotherapy, originally designated a breakthrough treatment for PTSD, now explores applications including major depressive disorder. MAPS expects to file an NDA with the FDA by end‑2024, with potential approval continuing into 2025 or 2026.

2. Regulatory Tailwinds Shape Outlook

FDA approval of ketamine‑derived Spravato in 2019 opened doors for psychedelic‑based depression therapies. More recently, the FDA signaled a more favorable stance toward psychedelics, evidenced by supportive comments from senior health officials and renewed momentum for drug candidates such as BPL‑003.

The regulatory environment for psychedelic therapies shows signs of opening:

• Multiple states and countries—such as Australia, New Zealand, the Czech Republic, Alberta (Canada), and Oregon (USA)—are approving or decriminalizing the medical use of substances like psilocybin, MDMA, and DMT in structured settings.
• Federal and state regulators in the U.S. signal interest through breakthrough therapy designations, off‑label ketamine use expansion, and increased legislative discussion.

3. Demand for Fast-Acting, Short Exposure Treatments Grows; Drug Market Remains Lifted by Growth and Demand

Patients and clinicians increasingly favor treatments that deliver rapid symptom relief while minimizing the duration of psychoactive effects. Bretisilocin’s 60–90‑minute activity window positions it advantageously alongside compounds like GH001 (5‑MeO‑DMT) that also offer brief but potent responses.

Market analysts report robust growth across the psychedelic‑therapeutics sector:

• Market size estimates for 2025 range from USD 3.07 billion to USD 4.08 billion, with forecasts reaching USD 9.6 to 12.9 billion by the early 2030s, reflecting CAGRs between 13% and 15%.
• The broader MDD treatment market currently measures around USD 12 billion and may grow to USD 15.8 billion by 2035, driven by demand for innovative therapies. 

4. Market Trajectory Remains Upward, Though Regulatory Hurdles Persist

Multiple forecasts signal strong compound annual growth rates across the psychedelic therapeutics space. However, regulatory hesitancy, trial ethics concerns, and patent controversies continue to complicate the path forward. Essentially, despite positive momentum, stakeholders caution about rising ethical and trial‑integrity concerns:

• Investigators retracted MDMA psychotherapy papers in 2024 due to misconduct, underscoring the necessity for trainer oversight and robust informed consent.
• Experts emphasize that sustained clinical evidence, structured trial design, and regulatory rigor will determine whether psychedelic modalities transition from promise to mainstream treatment.

Industry Outlook: What the Broader Psychedelic Landscape Suggests

Multiple forecasts show strong compound annual growth rates across the psychedelic therapeutics space. However, regulatory hesitancy and patent disputes complicate progress. Despite momentum, stakeholders warn that trial ethics and integrity concerns could slow broader adoption. Investigators retracted MDMA psychotherapy papers in 2024 due to misconduct. This highlighted the need for trainer oversight and rigorous informed consent in clinical practice.

Experts stress that sustained evidence, structured trials, and regulatory rigor will determine psychedelic treatments’ transition to mainstream use. Meanwhile, the therapeutic paradigm for major depressive disorder is shifting. Clinics move beyond reliance on SSRIs and SNRIs.

They are exploring neuromodulation, ketamine variants, and psychedelic-assisted therapies to fill critical treatment gaps. Developers like Tactogen test safer MDMA-like compounds. This diversification illustrates how the field is evolving with safety improvements in mind. In addition, advances in neurobiology reinforce these changes. Studies show psychedelics may enhance neuroplasticity by reopening developmental-like plasticity windows. Such mechanisms enable faster adaptation and recovery, lending credibility to rapid-acting antidepressant approaches. Consequently, patients and clinicians show increasing openness toward psychedelic-based therapies. This openness reflects compelling trial data and biological plausibility.

The combination of evidence, mechanistic insights, and market appetite suggests MDD therapies are entering accelerated transformation. Overall, psychiatry is moving into a period of rapid clinical and commercial change.

A Market on the Brink of Transformation

AbbVie’s acquisition of bretisilocin injects new energy into the MDD treatment landscape, signaling that big pharma views psychedelic-style medicines as both viable and necessary disruptors. The therapy’s rapid effects, shorter psychedelic episodes, and Phase 2 success dovetail with broader market growth trajectories. As regulatory attitudes evolve and clinical evidence mounts, stakeholders anticipate an era where fast-acting, mechanism-driven antidepressants complement or even supplant some legacy therapies—though success will hinge on maintaining scientific rigor, regulatory trust, and ethical stewardship.

Author

Bernice Lottering